Clinical aspects
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™)
O. Distler1, K.K. Brown2, J.H. Distler3, S. Assassi4, T.M. Maher5, V. Cottin6, J. Varga7, C. Coeck8, M. Gahlemann9, W. Sauter10, H. Schmidt11, K.B. Highland12
- University Hospital Zurich, Switzerland. oliver.distler@usz.ch
- National Jewish Health, Denver, Colorado, USA.
- University of Erlangen-Nuremberg, Erlangen, Germany.
- University of Texas Houston Medical School, Houston, Texas, USA.
- NIHR Biomedical Research Unit Royal Brompton Hospital, London, UK and Fibrosis Research Group, National Heart and Lung Institute, Imperial College London, UK.
- Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France.
- Feinberg School of Medicine, Chicago, Illinois, USA.
- SCS Boehringer Ingelheim Comm.V., Brussels, Belgium.
- Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
- Cleveland Clinic, Cleveland, Ohio, USA.
on behalf of the SENSCIS™ trial investigators
CER10460
2017 Vol.35, N°4 ,Suppl.106
PI 0075, PF 0081
Clinical aspects
Free to view
(click on article PDF icon to read the article)
PMID: 28664834 [PubMed]
Received: 31/03/2017
Accepted : 05/05/2017
In Press: 29/06/2017
Published: 12/10/2017
Abstract
OBJECTIVES:
Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF). The pathological pathways involved in fibrogenesis in IPF and interstitial lung disease associated with systemic sclerosis (SSc-ILD) show commonalities; both involve fibroblast activation, myofibroblast accumulation and deposition of extracellular matrix. The SENSCIS™ trial is a randomised, placebo-controlled Phase III trial that will evaluate the efficacy and safety of nintedanib in patients with SSc-ILD (NCT02597933).
METHODS:
Approximately 520 patients with SSc (based on 2013 American College of Rheumatology/European League Against Rheumatism criteria) and ILD (≥10% fibrosis of the lungs, confirmed by central assessment of chest high resolution computed tomography), forced vital capacity (FVC) ≥40% predicted and diffusing capacity for carbon monoxide of 30-89% predicted will be enrolled. Patients will be randomised (1:1) to nintedanib 150 mg twice daily or placebo, stratified by the presence of anti-topoisomerase I antibody. To reflect real-world management, patients receiving prednisone (≤10 mg/day) and/or a stable dose of mycophenolate or methotrexate, will be eligible. The primary endpoint is the annual rate of decline in FVC (mL/ year) assessed over 52 weeks. Patients will remain on blinded study treatment until the last patient completes 52 weeks of treatment or for a maximum of 100 weeks of treatment. Key secondary endpoints are absolute changes from baseline in modified Rodnan skin score and St George’s Respiratory Questionnaire at week 52.
RESULTS:
Recruitment for the trial began in November 2015.
CONCLUSIONS:
This trial will assess the efficacy and safety of nintedanib in patients with SSc-ILD.